RT Book, Section
A1 Gomez, Javier
A1 Doukky, Rami
A2 Heller, Gary V.
A2 Hendel, Robert C.
SR Print(0)
ID 1190157123
T1 Evaluation of Patients with Known Coronary Artery Disease
T2 Nuclear Cardiology: Practical Applications, 4e
YR 2022
FD 2022
PB McGraw Hill LLC
PP New York, NY
SN 9781264257201
LK accesscardiology.mhmedical.com/content.aspx?aid=1190157123
RD 2024/04/23
AB KEY  POINTSIn  patients  with  known  coronary  artery  disease  (CAD),  abnormal  single-photon  emission  computed  tomography  (SPECT)  or  positron  emission  tomography  (PET)  myocardial  perfusion  imaging  (MPI)  is  associated  with  an  increase  in  risk  of  adverse  cardiac  events,  proportional  to  the  extent  and  severity  of  the  perfusion  abnormalities.SPECT  and  PET  MPI  can  determine  extent,  severity,  and  localization  of  perfusion  abnormalities  in  patients  with  multivessel  CAD  or  prior  revascularization  procedures,  guiding  management  strategies.Routine  MPI  testing  after  coronary  revascularization  in  patients  with  stable  or  no  symptoms  is  not  supported  by  current  guidelines.SPECT  and  PET  MPI  provide  safe  and  effective  risk  stratification  in  patients  presenting  with  acute  coronary  syndromes  or  myocardial  infarction  who  have  not  received  or  have  a  contraindication  to  invasive  coronary  angiography.SPECT  and  PET  MPI  can  be  useful  to  assess  response  to  medical  therapy  in  patients  with  established  CAD.